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Abstract. Aim: The aim of this work was to synthesize and
study in vitro and in vivo nanocarriers used as magnetic
resonance imaging (MRI) contrast agents that accumulate
in tumor cells specifically overexpressing folate receptors.
Materials and methods: Nanoparticles were prepared by
self-assembly of poly-γ-glutamic acid and chitosan
biopolymers and were complexed with gadolinium ions.
Folic acid served as a targeting molecule. Rat
hepatocellular carcinoma (HeDe) cells overexpressing folate
receptors were used as a model system. For in vivo
experiments, HeDe cells were transplanted under the renal
capsule of F344 rats. Results: In vitro results showed the
significant internalization of nanoparticles into HeDe cells.
MRI measurements revealed that targeting nanocarriers
accumulated in tumors. The MRI/PET fusion images
resulted in the exact localization of tumors. Conclusion: The
nanocarrier provides a suitable means for the early
diagnosis of tumors based on their overexpression of folate
receptors.
The potential utility of nanosystems as improved contrast
agents for medical imaging has generated a great deal of
scientific activity in recent years. Nanosystems have the
potential to improve medical imaging by increasing the
specificity and sensitivity of images and to allow for the
combination of images from multiple modalities, increasing
the probability of earlier disease diagnosis and more
effective intervention. Several different contrast agents are
currently used to enhance sensitivity and to provide high
resolution soft-tissue contrast for magnetic resonance
imaging (MRI). The paramagnetic gadolinium-containing
contrast agents shorten the relaxation time of protons in
water to provide higher contrast at tumor sites relative to the
surrounding tissues based on the differing densities of tumor
vs. healthy tissues.
Targeted delivery is an emerging platform in nano-
medicine, therefore many studies have focused on the
development of efficient targeted delivery systems. A useful
strategy to achieve efficient tumor targeting is to conjugate
carriers with specific ligands that recognize and bind to their
cognate receptors on the surface of cancer cells. Targeting
ligands shown to be effective in pre-clinical and early
clinical studies include monoclonal antibodies (1, 2),
peptides (3-5), transferrin (6-8), somatostatin (9-10),
aptamers (11, 12) and folic acid (FA) (13-15).
Recent studies have indicated that FA receptors are
selectively overexpressed in a number of tumor cell types
(e.g. breast, ovarian, cervical, colorectal, renal, and
nasopharyngeal), but present in low or non-detectable levels
in most normal cells. FA has a low molecular weight, high
receptor affinity (16), and is internalized via receptor-
mediated endocytosis (17, 18), making it a good targeting
candidate for nanocarriers delivering a contrast agent to the
cell’s interior. 
Numerous publications attest to the efficacy of FA-
targeted nanoparticles. Nanocarriers including micelles (19,
20), dendrimers (21, 22), liposomes (23, 24), metallic
nanoparticles (25, 26), and polymeric nanoparticles (27, 28)
have been shown to be targeted to cancer cells by FA. 
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Molecular imaging plays a very important role in
molecular diagnosis. Molecular imaging enables
visualization of the targeted biological tissues and an
understanding of its complexities for diagnosis of the
disease. Real-time imaging of targeted tissues provides a
profound understanding of fundamental biological processes
and helps diagnose various diseases (29). Given the strengths
and weakness of specific imaging modalities, it is difficult
to obtain all the necessary information about the biological
structure and function of an organ using any single one,
therefore attempts are being made to fuse the advantages of
different imaging techniques by combining two or more
imaging modalities (30, 31). 
The fusion of MRI and PET images has proven to be
beneficial as it provides images of high sensitivity and high
resolution.
In cancer staging, integrated whole-body PET-MRI
provides a metabolic and anatomic image at the same time.
Thus, in vivo clinical studies may benefit from the
advantages of both modalities, such as high sensitivity of
positron emission tomography (PET) and the best resolution
of MRI. Another benefit compared to widely used PET-CT
(computed tomography) is that the MRI modality has no
radiation component. Progress in technological development
of PET detector technology and MRI-based PET attenuation
correction. To provide a new generation of contrast agents
for hybrid machines, two-in-one nanoparticulate systems are
in development for dual-modality use (32-34).
In our recent study, biodegradable poly-γ-glutamic acid
and biocompatible chitosan biopolymers were combined to
produce stable, self-assembled nanoparticles. The factors
determining the physicochemical properties of the
nanoparticles have been described previously (35). In vitro
cytotoxicity and in vivo toxicity studies demonstrated the
preferential uptake of FA-coupled nanoparticles by cancer
cells (36). 
The present investigation reports the synthesis and the
application of a biodegradable, macromolecular, folate-
targeted MRI contrast agent tested against the in vitro and in
vivo growth of hepatocellular carcinoma (HeDe) tumor cell
line. HeDe is a chemically-induced animal tumor cell line
which overexpresses extracellular FA receptor (37, 38).
In this study, in vitro results confirm that the nanocarriers
are internalized into the targeted HeDe tumor cells in a folate
receptor-dependent manner. For in vivo experiments, tumor
cells were transplanted under the renal capsule of F344 rats.
Using this method abdominal tumors and metastasis were
modeled.
MRI results support the conclusion that the targeted
nanocarriers accumulate in the tumor and change its
relaxation time. After i.v. 18F-FDG administration, tumor
localization was performed using our mini-PET method (see
Materials and Methods), and by fusing MRI-PET images
both anatomical and functional aspects were gained. This
combined method allows for identification of tumor
localization unequivocally, enabling early tumor diagnosis.
Materials and Methods
Materials. Chitosan [CH; degree of deacetylation (DD)=88%, Mv=320
kDa] was purchased from Sigma-Aldrich Co., Budapest, Hungary.
Chitosan was dissolved in 2.0% aqueous acetic acid solution to give a
polymer concentration of 1.0% (w/w), and then filtered and dialyzed
against distilled water until the pH of the water outside the dialysis
tubing became neutral. The product was dried by lyophilization to
obtain a white chitosan powder and used for further experiments. Poly-
γ-glutamic acid (γ-PGA; Mw=400 kDa) was purchased from the
Vedan Group, Taiwan. For purification, γ-PGA was dissolved in water
to give a polymer concentration of 1.0% (w/w), dialyzed against
distilled water, and freeze-dried to obtain purified γ-PGA for further
experiments. Water-soluble 1-[3-(dimethylamino)propyl]-3-
ethylcarbodiimide methiodide (EDC), FA dehydrate and
gadolinium(III)-chloride (GdCl3) hydrate were purchased from Sigma-
Aldrich Co., and were used without further purification. The sodium
salt of Alexa Fluor® 488 succinimidyl ester fluorescent dye was
purchased from Molecular Probes Eugene, OR, USA.
Synthesis of folated γ-PGA. FA was conjugated via the amino
groups to γ-PGA using the EDC technique: γ-PGA aqueous solution
(V=100 ml, 0.5 mg/ml, pH=6.5), was prepared, and EDC (10 mg in
distilled water) was added dropwise. The reaction mixture was
stirred at 4˚C for 1 h, then at room temperature for 1 h. FA (18 mg
dissolved in 4 ml dimethyl sulfoxide) was then added to the reaction
mixture and stirred at room temperature for 24 h. The folated poly-
γ-glutamic acid (γ-PGA-FA) was purified by dialysis against
distilled water for five days. 
Synthesis of fluorescently labeled chitosan. Aqueous solution of
chitosan was mixed with Alexa Fluor® 488 dye. Briefly, chitosan
was dissolved in 0.1 M hydrochloric acid, and then adjusted to pH
6.5 with 0.1 M sodium hydroxide solution. To 2 ml of chitosan
solution (1 mg/ml), 5 μl of Alexa Fluor® 488 dye (9.1 mg/ml) was
mixed and the reaction mixture was stirred at room temperature for
24 h. Fluorescently-labeled chitosan (CH-AF) was purified by
dialysis against distilled water for five days. 
Preparation of self-assembled nanoparticle gadolinium conjugate.
Stable self-assembled nanoparticles were prepared via an ionotropic
gelation process between the folated γ-PGA and fluorescently-
labeled chitosan linear chains. CH-AF solution was added into the
γ-PGA-FA solution under constant stirring. An opaque aqueous
colloidal system containing nanoparticles that remained stable at
room temperature for several weeks at physiological pH was
achieved. To produce paramagnetic contrast agent, the self-
assembled nanoparticles were conjugated with Gd3+. The solution
of GdCl3 was added dropwise to the aqueous colloid system
containing targeted self-assembled nanoparticles and stirred at room
temperature for 30 min. The schematic view of the self-assembled
nanoparticle-gadolinium complex (γ-PGA-FA/CH-AF–Gd) is shown
in Figure 1. 
Non-targeted nanoparticles complexed with Gd-ions were also
prepared by self-assembly of folate-free γ-PGA and fluorescently
labeled chitosan as a control for in vitro studies.
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Characterization of nanoparticles. The hydrodynamic size of particles
was measured by dynamic light scattering (DLS) using a Zetasizer
Nano ZS (Malvern Instruments Ltd., Grovewood, Worcestershire,
UK). This system is equipped with a 4 mW helium/neon laser with a
wavelength of 633 nm and measures particle size with noninvasive
backscattering technology at a detection angle of 173˚. Measurements
were performed using a particle-sizing cell in automatic mode. The
mean hydrodynamic diameter was calculated from the autocorrelation
function of the intensity of light scattered from the particles.
Electrokinetic mobility of the nanoparticles was determined in a
folded capillary cell (Malvern) with a Zetasizer Nano ZS apparatus.
Transmittance of the nanoparticle solution was measured with a
Hitachi U-1900 spectrophotometer (Hitachi High-Technologies
Corporation. Tokyo, Japan) at an operating wavelength of λ=500 nm
in optically homogeneous quartz cuvettes. Measurements were
repeated three times, and their average value was calculated. The
morphological characterization of nanoparticles in dried state was
carried out with a Hitachi 3000N scanning electron microscope
(Hitachi Science Systems Ltd., Japan) (SEM).
Cell culture. Hepatocellular carcinoma (HeDe) cell line (38) was
cultured as an exponentially-growing monolayer in RPMI 1640
supplemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin and 100 μg/ml streptomycin (37˚C, 5% CO2), passaged
daily. Cell viability was more than 95%, as assessed by trypan blue
dye exclusion.
MTT assay. The toxicity of the γ-PGA-FA/CH-AF-Gd nanoparticles
on hepatocarcinoma cells (HeDe) was investigated using MTT assay.
HeDe cells (1.5×103) were seeded in 96-well plates (BD Falcon,
Germany) and incubated overnight. Cells incubated with cell growth
medium (RPMI 1640) served as negative controls. γ-PGA-FA/CH-
AF-Gd nanoparticles were diluted in HeDe cell growth medium to
30 μg nanoparticles/ml then 100 μl cell growth medium and
nanoparticle-containing medium was added to each well. Cells were
incubated for 24 h. After the incubation, the medium was removed
and 10 μl MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) (5 mg/ml) was added. After 3 h incubation, 100 μl dimethyl
sulfoxide was added to each well. The optical density of wells were
measured with a microplate reader at λ=492 nm.
Confocal microscopy of cellular uptake of nanoparticles. Equal
number of HeDe cells (2×104 per well) were plated in an 8-well cell
culture chamber. Ten microliters of nanoparticle – gadolinium
conjugate was added to the cells at a concentration of 0.3 mg/ml per
well and cells were then incubated at 37˚C for 24 h in RPMI
medium. The medium was removed by aspiration and wells were
washed consecutively with 400 μl of cold phosphate buffered saline
(PBS), citrate buffer solution and PBS. The fixation was performed
with 300 μl/well of fresh 1% formaldehyde in PBS at 4˚C for 10 min.
Samples were imaged by an Olympus FluorView 1000 confocal
microscope (Olympus, Tokyo, Japan) using a ×60 UPLSAPO oil
immersion objective. Excitation of Alexa Fluor® was performed at
488 nm wavelength by an Ar ion laser and detection of images at
500-550 nm. Images were analyzed using the Olympus FluoView
FV10-ASW 1.5 software package (Olympus, Tokyo, Japan).
Pre-treatment of HeDe cells with free FA. To test whether
nanoparticle uptake occurs via folate receptors, 4 μl FA (11 mg/ml
in dimethyl sulfoxide) was added to the tumor cells to saturate
receptors. Cells were incubated with free FA at 37˚C for 1 h, and
then treated with nanoparticles.
Flow cytometry. HeDe cells were plated at a density of 1 million
cells per T flask (75 cm2), and then incubated in a 5% (v/v) CO2
humidified atmosphere at 37˚C for 24 h in RPMI. After culturing
cells to sub-confluency (80-90%), 1 ml of γ-PGA-FA/CH-AF–Gd
contrast agent (0.3 mg/ml) was added to each T flask and cells were
incubated at 37˚C for an additional 24 h. After the incubation, the
medium was removed and cells were washed, trypsinized (0.25%
trypsin/0.05% EDTA) and centrifuged. The cell pellet was dissolved
in fresh 2% formaldehyde in PBS.
Flow cytometric analysis (BD FACSArray Bioanalyzer System,
BD Biosciences, Franklin Lakes, NJ, USA) was carried out with a
single-cell suspension, and only the live cells were gated based on
forward and side scatter dot plots. Data are given as the mean
channel fluorescence of the cell population.
Magnetic resonance imaging in vitro. HeDe cells (2×106 in 15 ml
RPMI-1640) were incubated with folate-targeted γ-PGA-FA/CH-
AF–Gd and non-folated γ-PGA/CH-AF–Gd nanoparticles.
Nanoparticles (1.5 ml) at a concentration of 0.3 mg/ml were added
to the cells and incubated at 37˚C for 24 h in RPMI-1640 medium.
After the incubation, the medium was removed and cells were
washed with PBS and trypsinized using 2 ml of trypsin/EDTA
(0.25%/0.05%) and centrifuged. The cell pellet obtained was re-
suspended in 200 μl sterile PBS. Vials containing cell suspensions
were kept in a container filled with distilled water during the
measurement. T1-Weighted signal intensities were measured by a
clinical 1.5 T GE Signa LX MR scanner (GE Healthcare Waukesha,
WI, USA). The pulse sequences were TR=420.0 ms and TE=20.0
ms; thickness: 1.5 mm and space: 0 during the measurements. 
Recipient animal model. In each experiment, adult male Fischer 344
(F344) rats (Charles River Mo Kft., Gödöllő, Hungary), weighting
150-200 g, were used (n=10). Rats were kept in a conventional
laboratory environment and fed a semi-synthetic diet (Charles River
Mo, Kft, Godollo, Hungary) and tap water ad libitum. Animals
received human care to the criteria outlined in the "Guide for the
Care and Use of Laboratory Animals” (39) authorized by the Ethical
Committee for Animal Research, University of Debrecen, Hungary
(permission number: 22/2007).
Experimental tumor. We used the hepatocellular carcinoma
(Hepatocarcinoma Debreceniensis, HeDe) isolated from Fischer 344
rats which were treated at newborn age by injecting i.p. 125 μg/
animal N-nitroso-dimethylamine (Sigma-Aldrich Kft, Budapest,
Hungary) in saline. Tumors were removed 5-7 months after
chemical tumorogenesis, minced into smaller pieces and tumor
slices were frozen and the HeDe cell line was established (37, 40). 
Experimental surgery. For transplantation 106 cells (HeDe cell line)
in 10 μl saline were placed on GelasponR disc (Germed, Rudolstadt,
Germany). Experimental animals were anesthesized by
intraperitoneal administration of 6 mg/100 g body weight
pentobarbital (Nembutal, CevaPhylaxia Rt. Budapest, Hungary). The
retroperitoneum was opened by abdominal section, the left kidney
was exposed and the tumor cell containing gelatin disc was placed
under the renal capsule (40). Stitches were put in the wound and in
vivo experiments followed 10 days later.
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Magnetic resonance imaging in vivo. For MRI imaging, tumor-
bearing rats (n=5) were injected with targeted nanoparticle-
gadolinium complex as an MRI contrast agent via the tail vein 24 h
before the MRI investigation, at the dosage of 17.3 μmol Gd/kg.
After this incubation time, the rats were anaesthetized with
pentobarbital (Nembutal; 6 mg/100 g body weight). T1-Weighted
MR images were performed using a clinical 1.5 T GE Signa LX MR
scanner. The pulse sequences were TR=420.0 ms and TE=20.0 ms;
thickness: 1.5 mm and space: 0 during the measurements.
Comparison of tumor signal intensity between γ-PGA-FA/CH-
AF–Gd contrast agent-treated and control groups were calculated
using an unpaired Student’s t-test. All data were tested to be normal
distributed by means of Kolmogorov-Smirnov test. Data are reported
as the mean±SD and p≤0.05 was considered statistically significant.
PET imaging in vivo. A small-animal PET scanner (MiniPET-II,
Debrecen, Hungary; www.minipetct.hu) was used for in vivo
imaging. The MiniPET-II small animal PET scanner consists of 12
detector modules in one ring with LYSO scintillator crystal blocks
and position-sensitive photomultiplier tubes (Hamamatsu H9500).
Each crystal block comprises 35×35 pins of 1.27×1.27×12 mm size
(pitch size of 1.35 mm). The sensitivity value in the center of the
field of view (FOV) is 6.3 cps/kBq and the system’s absolute
sensitivity is 11.4% (NEMA-NU4 2008). The axial and the radial
FOV are 48 mm and 106 mm, respectively.
For PET imaging, tumor bearing rats were injected 15±2 MBq
18F-FDG via the tail vein. One hour after tracer injection rats were
anaesthetized with pentobarbital (Nembutal; 6 mg/100 g body
weight) and static PET data were acquired for 10 min at each bed
position (five bed positions/rat). The collected data were subjected
to a rebinning algorithm and an ML-EM iterative method to
reconstruct the images (voxel size: 1.34×0.2×0.2 mm3).
Results
Formation of tumor-targeted nanoscopic MRI contrast agent.
Folate-targeted, self-assembled nanoparticles were formed
from biopolymers based on an ionotropic gelation process.
The nanoparticles can make stable complexes with Gd ions
to obtain paramagnetic contrast agent. The physicochemical
properties of the γ-PGA-FA/CH-AF–Gd nanoparticular
contrast agents were studied.
At a biopolymer concentration of 0.3 mg/ml, the
transmittance of nanoparticles was 85%. The aqueous
solution of nanoparticles was slightly opalescent and stable
for several weeks. The hydrodynamic size of the
nanoparticles was 130±4 nm with a relatively narrow size
distribution between 70 and 280 nm (Figure 2a)
(nanoparticles were suspended in 5% glucose solution, which
was also used in the in vivo experiments). Dried
nanoparticles were visualized by SEM micrograph (Figure
2b), and confirmed to be of an estimated size variation
between 50 and 150 nm. The mobility of nanoparticles was
μ=–3.8±0.3 μmcm/Vs at pH 7.4. 
Cytotoxicity of γ-PGA-FA/CH-AF-Gd. The viability of HeDe
cells treated with γ-PGA-FA/CH-AF-Gd nanoparticles was
investigated using the MTT assay. The MTT assay indicated
no significant change in cell viability at 30 μg/ml
nanoparticle concentration, which is suited to cell labeling.
Cellular uptake of γ-PGA-FA/CH-AF–Gd contrast agent.
Specific cellular uptake of nanoparticles by HeDe cancer
cells overexpressing folate receptors was tested by using
confocal microscopy. Figure 3 shows the confocal
microscopic fluorescence images of the HeDe cells incubated
with targeting (Figure 3a) and non-targeting (Figure 3b)
contrast agent. The folated γ-PGA-FA/CH-AF–Gd
nanoparticles accumulated in the cancer cells to a
significantly greater extent than their non-folated
counterparts. 
To confirm the receptor specificity of cellular uptake,
HeDe cells were incubated with free folic acid to block or
drastically reduce folate receptors held on the surface of
cancer cells prior to treatment with targeting γ-PGA-FA/CH-
AF−Gd contrast agent. FA-treated cells serve as a model of
healthy cells, which express only a low number of folate
receptors. Figure 3c shows that the targeting nanoparticles
do not internalize into the model healthy cells compared with
the HeDe tumor cells overexpressing folate receptors
supporting a specific, receptor-dependent uptake mechanism. 
Figure 3d shows optical slices of HeDe cells treated with
folate-targeting γ-PGA-FA/CH-AF–Gd contrast agent. The
microscopic images show that targeted nanoparticles entered
the cell and were present in the cytoplasm with the notable
exception of the round nucleus in the middle of the cell. 
Flow cytometric analysis of folate receptor dependent
nanoparticle uptake. The tumor cell targeting efficacy of
folate-targeted nanoparticulate contrast agent and non-folated
nanoparticles was compared using FACS analysis. HeDe
cells incubated with folate-targeted nanoparticles, a
significant shift in fluorescence spectrum was observed
relative to the control, non-treated HeDe cells while only
minor spectral displacement was registered relative to cells
incubated with non-folated nanoparticles (Figure 4). 
In vitro MR investigation. The T1-weighted MRI of tumor
cell suspensions treated with the nanoparticles were recorded
to test the efficacy of nanoparticles as a potential MR
contrast agent (Figure 5). The control cell suspension (Figure
5a) similarly to the MR images of HeDe cells incubated with
non-folated γ-PGA/CH-AF–Gd nanoparticles generated low
signal intensity due to the low level of internalized
nanoparticles (Figure 5b). Folated nanoparticles internalized
and accumulated in the targeted tumor cells, which appears
as a bright enhancement (Figure 5c). The signal intensities
of the control cells and cell suspension incubated with non-
folated nanoparticles were similar, 441 and 511 on the
densitometer scale, respectively. On the contrary, the signal
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intensity value of HeDe cell suspension incubated with
folated nanoparticles was 869, significantly higher than the
previous values, appearing as a bright area. 
In vivo MRI investigation. The folate-mediated in vivo uptake
of γ-PGA-FA/CH-AF–Gd contrast agents was evaluated
using Fischer 344 rats bearing HeDe tumors (n=10). Animals
(n=5) treated with 5% glucose solution served as a control.
Tumor-bearing rats were imaged with T1-weighted MR
(Figure 6 a and b). There was a significantly stronger
increase in signal intensity in tumors 24 h after intravenous
injection of γ-PGA-FA/CH-AF–Gd compared to control.
Comparing the signal intensity values significant (p<0.001)
differences were found between the control and the γ-PGA-
FA/CH-AF–Gd-treated tumors. The signal intensities of
control and treated tumors were 396.8±7.3 and 595.2±3.4,
respectively (Figure 6c).
The anatomy of the rat model is exhibited by MRI (Figure
7a), which reveals the location of the tumor. The PET image
(Figure 7b) shows the metabolism, suggesting the existence
of the tumor but gives minimal information about its location
because the contours of the surrounding organs are not
visible as they are in the MRI. 
Fusion of MR and PET images (Figure 7c) combine
anatomic and metabolic information. Colored parts of the
fusion image show the enhanced metabolism of the tumor,
while the anatomic picture provided by MRI allows for its
accurate localization.
Discussion
Formation of tumor-targeted nanoscopic MRI contrast agent.
Nanoparticles were prepared as a contrast agent that would
increase the signal of MRI. γ-PGA and chitosan biopolymer
formation took place via an ionotropic gelation process.
Nanoparticles assembled into a stable complex with Gd3+
ions, changing the local magnetic field and thereby
increasing MR signals and providing a suitable MRI contrast
agent. Chitosan was fluorescently-labeled to facilitate the
visual observation of the contrast agent by confocal
microscopy or detection by flow cytometry. FA as targeting
ligand was conjugated to the γ-PGA biopolymer allowing
nanoparticles to be internalized by cancer cells
overexpressing folate receptors. Conjugates lacking FA
served as a control in cellular uptake studies.
Cellular uptake of γ-PGA-FA/CH-AF–Gd contrast agent.
Nanoparticles containing FA as targeting ligand bound to
HeDe cells overexpressing folate receptors and were
efficiently internalized (Figure 3a). In contrast, particles
lacking FA did not penetrate the cell membrane (Figure 3b),
in fact their non-sepcific adsorption to the cell membrane
was negligible as well.
To confirm the receptor specificity of cellular uptake,
HeDe cells were incubated with free FA to block folate
receptors held on the surface of cancer cells prior to
treatment with targeting γ-PGA-FA/CH-AF−Gd contrast
agent. The targeting nanoparticles were not taken up into the
model healthy cells (Figure 3c) compared with the HeDe
tumor cells overexpressing folate receptors, supporting a
specific, receptor-dependent uptake mechanism. 
Optical slices of HeDe cells after treatment with folate-
targeting contrast agent (Figure 3d) indicate that our contrast
agent developed into folate-targeted nanoparticles was
internalized into HeDe cells. To the contrary, there was no
significant accumulation of the nanoparticles when they
lacked folate or when the cell surface was saturated with free
FA to mimic healthy cells expressing only few folate
receptors. This observation suggests that by using tumor-
specific contrast agents, side-effects can be minimized. 
Flow cytometric analysis of folate receptor-dependent
nanoparticle uptake. FACS analysis of HeDe cells (Figure 4)
confirmed the specific internalization and accumulation of
folated nanoparticles in the targeted tumor cells. In sharp
contrast to the folated nanoparticles, the spectral shift of non-
folated γ-PGA/CH-AF−Gd nanoparticles was minimal
compared to the controls. These results support the folate
receptor-specific uptake of nanoparticles. FA as targeting
ligand is required for the targeted internalization. The
insignificant accumulation of non-folated nanoparticles in
tumor cells suggests that their side-effects can be minimized. 
In vitro MR investigation. To directly verify that folated
nanoparticles targeting HeDe cells can be used as MRI
contrast agents, studies with an MRI scanner were
undertaken. T1-Weighted MRI were observed to test the
efficacy of nanoparticles as a potential MRI contrast agent
(Figure 5). The folated nanoparticles internalized and
accumulated in the targeted tumor cells (Figure 5c), and their
paramagnetic properties caused a reduction in the T1
relaxation time, thereby changing the signal intensity,
appearing as a bright enhancement. The MRI of control cell
suspension (Figure 5a) and HeDe cells incubated with non-
folated nanoparticles (Figure 5b) resulted in a similar darker
area with low signal intensity values. The non-folated
nanoparticles due to the low level of their internalization do
not change the relaxation time and signal intensity of tumor
cells. On the contrary, the signal intensity value of HeDe cell
suspension incubated with folated γ-PGA-FA/CH-AF–Gd
nanoparticles was significantly higher due to their effective
internalization.
In vivo MRI investigation. Fischer rat models were used for
the in vivo experiments. HeDe cells were transplanted under
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the renal capsule of left kidney of animals, and the tumor-
bearing animal models were imaged 10 days later.
The MRI provides the anatomic image of the animal. The
folated, targeting γ-PGA-FA/CH-AF–Gd contrast agent
internalized preferentially in tumor cells due to their
overexpression of folate receptors. The accumulation of
nanoparticles caused signal enhancement due to the presence
of the paramagnetic Gd ligand, in steep contrast to the
surrounding tissue, aiding in the exact localization of the
tumor. These changes in signal intensities can also be clearly
seen in the T1-weighted MRI (Figure 6a and b). The high
uptake of γ-PGA-FA/CH-AF–Gd by the tumor indicates that
the accumulation is related to folate-mediated endocytosis.
This finding supports the conclusion that the folate-targeting
γ-PGA-FA/CH-AF–Gd contrast agents were internalized
preferentially in tumor cells as they are overexpressing folate
receptors.
The MRI confirms that the folated nanoparticles
accumulate in the targeted tumor cells, and due to the
transported paramagnetic ions, change the relaxation time,
appearing as a bright contrast. The PET image shows the
metabolism and supports the tumor localization.
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Figure 1. Schematic representation of the targeted nanocarrier gadolinium complex.
Figure 2. Hydrodynamic size distribution (a) and SEM micrograph (b) of γ-PGA-FA/CH-AF–Gd contrast agent.
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Figure 3. Confocal microscopic images of HeDe cells treated with folate-targeting γ-PGA-FA/CH-AF–Gd (a), non-folated γ-PGA/CH-AF–Gd (b),
and folate-targeting γ-PGA-FA/CH-AF–Gd after incubating cells with free folic acid (c); and confocal microscopic sections of a HeDe cancer cells
incubated with γ-PGA-FA/CH-AF–Gd nanoparticles (z-series: 1.5 μm/slice thickness; from the bottom of the cell to the top) (d).
Fusion image slices of MRI and PET images (shown in
Figure 7c) are useful in early tumor diagnosis as they
combine the anatomic and metabolic information. PET part
of the fusion image slices clearly exhibit the presence of the
tumor, while the MRI part of picture provided its accurate
localization.
Conclusion
This work describes the preparation, the in vitro and in vivo
investigation of a novel, targeted, nanosized MRI contrast
agents. Stable, folate-targeted nanoparticles as potential MRI
contrast agents were obtained by the self-assembly of
biopolymers containing paramagnetic gadolinium ions. 
In vitro experiments confirmed that a significant
proportion of these nanoparticles were internalized and
selectively accumulated in targeted tumor cells that
overexpress folate receptors. The results demonstrated that
cellular uptake was folate receptor-dependent. Non-folated
nanocarriers did not enter the cell membrane as their
receptors could not recognize these particles.
The specificity of folate binding is expected to minimize
the side-effects of folated nanoparticles. In vivo MRI contrast
enhancement of folate-targeted nanoparticles was verified by
using our F344 rat tumor model. 
Fusion images were obtained by the combination of PET
and MRI of tumor-bearing rats treated with folate-targeted
nanoparticles visualizing simultaneously the anatomy and
metabolism of the animal. 
Our targeted nanoparticles are potential MRI contrast
agents for diagnostic applications, and have the additional
potential to be developed into delivery systems for
therapeutic agents.
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Figure 4. FACS analysis of nanoparticle uptake. Folate-dependent uptake of nanoparticles was detected as described in the Methods. a) Fluorescence
histograms of untreated HeDe cells (red), HeDe cells treated with folate-targeted γ-PGA-FA/CH-AF–Gd (blue) and non-folated γ-PGA/CH-AF–Gd
nanoparticle (green). b) Mean fluorescence intensities of nanoparticles.
Figure 5. T1-Weighted MR images of control HeDe cells (a), HeDe cell suspensions incubated with non-folated γ-PGA/CH-AF–Gd nanoparticles (b)
and with folate-targeted γ-PGA-FA/CH-AF–Gd (c).
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Figure 6. Study on the uptake of γ-PGA-FA/CH-AF–Gd into HeDe tumors (a, b). The T1-weighted MRI (coronal slices) of Fischer 344 rats bearing
HeDe tumors post-intravenous injection of 5% glucose solution as control (a) and γ-PGA-FA/CH-AF–Gd contrast agent (b). The increase in signal
intensity of γ-PGA-FA/CH-AF–Gd can be visualized in treated HeDe tumors (b). Much less effect can be seen in the control tumor. (c) The graph
also shows the significantly different signal intensity values between control and treated tumors.
Figure 7. Representative section of T1-weighted MR image (a) and PET image (b) and fusion image (c) of γ-PGA-FA/CH-AF–Gd-treated tumor-bearing
rat. The fusion image combines the anatomic and metabolic information, which can facilitate early tumor diagnosis and accurate localization.
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